MSD’s Keytruda scores impressive first-line lung cancer data
pharmafile | May 24, 2018 | News story | Research and Development, Sales and Marketing | MSD, biotech, drugs, keytruda, pharma, pharmaceutical
MSD Keytruda has enjoyed the most success of the PD-1/L1 therapies in clinical trials recently and it’s rapidly cementing its position as the leader in the field with another set of stellar data, this time in metastatic squamous non-small cell lung cancer on a first-line basis.
Keytruda was used in conjunction with chemotherapy and managed to hit both its primary endpoints in overall survival and progression-free survival.
However, the company is holding back the exact data until the ASCO meeting at the beginning of next month – it only referenced the fact that interim analysis suggested that OS and PFS was “significantly longer” compared to patients being to treated with chemotherapy alone.
“As first-line treatment, Keytruda in combination with traditional chemotherapy has now demonstrated an improved survival benefit, compared to chemotherapy alone, in metastatic lung cancer patients with squamous histology,” said Dr Roger M. Perlmutter, President, Merck Research Laboratories. “We look forward to presenting the overall survival and progression-free survival findings from KEYNOTE-407 at the 2018 ASCO Annual Meeting, and are grateful to the patients and investigators for their important contributions to this pivotal study.”
MSD will use the new data to move forward with the FDA in gaining a new indication for the drug, potentially joining numerous existing indications across lung cancer, head and neck cancer, melanoma, amongst others.
There are estimates that, in this possible indication, Keytruda could bring in upwards of $6 billion.
This bevy of indications has seen Keytruda slowly claw back the early lead built by BMS’ Opdivo and, with a potential conveyer belt of further indications through its 753 further trials, it looks likely it will surpass its close rival in sales.
Ben Hargreaves
Related Content
Amphista doses first patient in AML trial of protein degrader
Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an …
Digital platform cuts pharmaceutical quality-record approval times by up to 90%
A digital platform for exchanging pharmaceutical quality records between supply-chain partners is now commercially available, …
Agentic commercial: how AI creates dialogue with HCPs and patients to help medicines reach them faster
By Chris Moore Commercial engagement in biopharma used to centre largely on direct conversations between …
